血清VCAM-1、FGF2等炎症因子与难愈性糖尿病足的相关性研究

doi:10.3969/j.issn.1673-8640.2014.05.010

检验医学 ›› 2014, Vol. 29 ›› Issue (5): 472-476.DOI: 10.3969/j.issn.1673-8640.2014.05.010

血清VCAM-1、FGF2等炎症因子与难愈性糖尿病足的相关性研究

张莹¹, 王伟灵², 杨沁彤³, 赵静静¹, 周丽霞², 邢嘉翌², 赵延荣²

1.蚌埠医学院, 安徽蚌埠 233030;
2.上海市中西医结合医院检验科, 上海 200082;
3.上海市中西医结合医院脉管科, 上海 200082

收稿日期:2014-01-08 出版日期:2014-05-30 发布日期:2014-05-27
通讯作者: 王伟灵, 联系电话:021-65415910-6706。
作者简介:张莹, 女, 1990年生, 学士, 主要研究方向为代谢性疾病诊断。
基金资助:
上海市科学技术委员会医学引导类项目(124119b2000)

Study on the correlationship of serum VCAM-1, FGF 2 and other inflammatory cytokines with refractory diabetic foot

ZHANG Ying¹, WANG Weiling², YANG Qintong³, ZHAO Jingjing¹, ZHOU Lixia², XING Jiayi², ZHAO Yanrong².

1.Bengbu Medical College, Anhui Bengbu 233030, China;
2.Department of Clinical Laboratory, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai 200082, China;
3. Department of Clinical Vasculature, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai 200082, China

Received:2014-01-08 Online:2014-05-30 Published:2014-05-27

摘要/Abstract

摘要： 目的探讨血管细胞黏附分子-1(VCAM-1)和成纤维细胞生长因子2(FGF2)等炎症因子与难愈性糖尿病足(DF)发生、发展的关系。方法收集145例难愈性DF患者(DF组)和65例无足部溃疡的2型糖尿病(T2DM)患者(T2DM组)的基本临床资料, 采集空腹血检测VCAM-1、FGF2、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA_1c)、糖化白蛋白(GA)、C反应蛋白(CRP)、纤维蛋白原(FIB)、白细胞计数(WBC)和中性粒细胞比率(Neu%), 并对结果进行统计分析。将DF组参照Wagner分级方法分为Wagner Ⅲ级(37例)、Wagner Ⅳ级(92例)和Wagner Ⅴ级(16例)。结果 DF组和T2DM组之间性别构成、体重指数(BMI)、FBG、2 hPG、HbA_1c和GA差异均无统计学意义(P>0.05)。DF组VCAM-1、FGF2、TNF-α、IL-6、WBC、Neu%、FIB、CRP、年龄、糖尿病病程和心率均高于T2DM组(P<0.01)。TNF-α与VCAM-1呈正相关(r=0.284, P=0.000)。单因素Logistic回归分析表明VCAM-1、FGF2、TNF-α、IL-6、年龄、糖尿病病程、心率、WBC、Neu%、FIB和CRP是DF发生的危险因素。多因素Logistic回归分析显示VCAM-1、TNF-α、FIB和Neu%为DF发生的独立风险因素。WagnerⅤ级组年龄低于Wagner Ⅲ级组和Wagner Ⅳ级组(P<0.01), 而IL-6、CRP、FIB、WBC、Neu%均高于Wagner Ⅲ级组和Wagner Ⅳ级组(P<0.05、P<0.01)。WagnerⅤ级组FGF2和HbA_1c高于Wagner Ⅲ级组(P<0.05)。结论血清VCAM-1、FGF2等炎症因子水平升高在DF发生、发展过程中起到重要作用。DF治疗中应注重抗炎治疗。

关键词: 血管细胞黏附分子-1, 成纤维细胞生长因子2, 肿瘤坏死因子-α, 白细胞介素-6, 炎症因子, 糖尿病足

Abstract: Objective To investigate the relationship of vascular cell adhesion molecule-1 (VCAM-1), fibroblast growth factor 2 (FGF2) and other inflammatory cytokines with the occurrence and development of refractory diabetic foot(DF). Methods A total of 145 patients with refractory DF (DF group) and 65 patients with type 2 diabetes mellitus(T2DM) and non-foot ulcers (T2DM group) were enrolled for the basic clinical data, and fasting blood were collected for the determinations of VCAM-1, FGF2, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), fasting blood glucose (FBG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin A_1c(HbA_1c), glycated albumin (GA), C-reactive protein (CRP), fibrinogen (FIB), white blood cell count (WBC) and neutrophil ratio (Neu%). The results were analyzed statistically. According to Wagner grade, DF group was classified into Wagner Ⅲ(37 cases), Wagner Ⅳ(92 cases) and Wagner Ⅴ(16 cases). Results Between DF and T2DM groups, sex, body mass index (BMI), FBG, 2 hPG, HbA_1c and GA had no statistical significance (P> 0.05). The levels of VCAM-1, FGF2, TNF-α, IL-6, WBC, Neu%, FIB, CRP, age, duration of diabetes and heart rate in DF group were significantly higher than those in T2DM group(P<0.01).TNF-α was significantly correlated with VCAM-1(r=0.284, P=0.000).Univariate Logistic regression analysis showed that VCAM-1, FGF2, TNF-α, IL-6, age, duration of diabetes, heart rate, WBC, Neu%, FIB and CRP were risk factors for DF occurrence. Multivariate Logistic regression analysis showed that only VCAM-1, TNF-α, FIB and Neu% were the independent risk factors of DF occurrence. The age of Wagner Ⅴ group was significantly lower than those of Wagner Ⅲ and Ⅳ groups(P<0.01), and serum IL-6, CRP, FIB, WBC and Neu% were significantly higher than those of Wagner Ⅲ and Ⅳ groups(P<0.05, P<0.01 ). The levels of FGF2 and HbA_1c in Wagner Ⅴ group were significantly higher than those in Wagner Ⅲ group(P<0.05). Conclusions The elevated levels of serum VCAM-1, FGF2 and other inflammatory cytokines play important roles in the occurrence and development of DF, and we should pay more attention to anti-inflammatory therapy when treating DF.

Key words: Vascular cell adhesion molecule-1, Fibroblast growth factor 2, Tumor necrosis factor-alpha, Interleukin-6, Inflammatory cytokine, Diabetic foot

中图分类号:

R446.1

张莹, 王伟灵, 杨沁彤, 赵静静, 周丽霞, 邢嘉翌, 赵延荣. 血清VCAM-1、FGF2等炎症因子与难愈性糖尿病足的相关性研究[J]. 检验医学, 2014, 29(5): 472-476.

ZHANG Ying, WANG Weiling, YANG Qintong, ZHAO Jingjing, ZHOU Lixia, XING Jiayi, ZHAO Yanrong.. Study on the correlationship of serum VCAM-1, FGF 2 and other inflammatory cytokines with refractory diabetic foot[J]. , 2014, 29(5): 472-476.

参考文献

[1] Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes[J]. JAMA, 2005, 293(2): 217-228.
[2] 张妲, 关小宏.糖尿病足溃疡与炎症[J].中国老年学杂志, 2013, 33(2):493-495.
[3] Bakker K, Apelqvist J, Schaper NC, et al. Practical guidelines on the management and prevention of the diabetic foot 2011[J]. Diabetes Metab Res Rev, 2012, 28(Suppl 1):225-231.
[4] Wagner FW Jr. The dysvascular foot:a system of diagnosis and treatment[J]. Foot Ankle, 1981, 2(2):64-122.
[5] 李秀钧, 邬云红.糖尿病是一种炎症性疾病[J].中华内分泌代谢杂志, 2003, 19(4):251-253.
[6] Weigelt C, Rose B, Poschen U, et al.Immune mediators in patients with acute diabetic foot syndrome[J]. Diabetes Care, 2009, 32(8):1491-1496.
[7] Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration[J]. Diabetes, 2012, 61(11):2937-2947.
[8] 唐可京, 谢灿茂, 李幼姬.细胞间粘附分子-1和血管细胞间粘附分子-1的结构与功能[J].细胞与分子免疫学杂志, 2002, 18(2):193-195.
[9] 徐茂锦, 邹大进, 叶江洪.高糖、晚期糖化终产物对微血管内皮细胞VCAM-1表达的影响[J].解放军医学杂志, 2002, 27(7):618-619.
[10] 吴煜, 熊瑛, 崔驰.FGF-2的非酶糖基化修饰及对糖尿病血管病变的影响[J].中外医疗, 2009, 28(23):14-15.
[11] Xu J, Wu HF, Ang ES, et al. NF-kappa B modulators in osteolytic bone diseases[J].Cytokine Growth Factor Rev, 2009, 20(1):7-17.
[12] Uccioli L, Sinistro A, Almerighi C, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot[J].Diabetes Care, 2010, 33(2):350-355.
[13] 陈立立, 胡仁明.2型糖尿病发病的炎症机制[J].中华糖尿病杂志, 2012, 4(4):248-251.
[14] 王伟灵, 赵延荣, 周丽霞, 等.糖尿病足坏疽患者血脂、凝血功能与踝肱指数的相关性分析[J].检验医学, 2010, 25(11):897-900.
[15] Rattan R, Nayak D. High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patient with diabetic foot wounds: a preliminary communication[J].Int J Low Extrem Wounds, 2008, 7(4):198-203.
[16] 孙好杰, 王鹏华, 丁敏, 等.糖尿病足截趾患者的转归——5年的随访研究[J].中华内分泌代谢杂志, 2012, 28(3):201-206.

血清VCAM-1、FGF2等炎症因子与难愈性糖尿病足的相关性研究

Study on the correlationship of serum VCAM-1, FGF 2 and other inflammatory cytokines with refractory diabetic foot

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	彭伟, 李运改, 许静, 刘华, 杨翠霞, 沈云岳. 血清炎症因子联合PSA、f-PSA可辅助诊断前列腺癌[J]. 检验医学, 2023, 38(9): 849-854.
[2]	刘亚楠, 夏敏, 胡韶华, 郑月, 张泓. 淋巴细胞亚群、炎症因子和氨基末端B型钠尿肽原联合检测诊断川崎病[J]. 检验医学, 2023, 38(6): 532-537.
[3]	滑世轩, 代淑阳, 李冰洁, 岑东, 许泼实. 血脂正常冠心病患者炎症因子水平与病情严重程度的关系[J]. 检验医学, 2023, 38(1): 66-68.
[4]	张城, 费春霞, 付琳, 高辰飞, 倪冬英. 糖尿病足患者FGF-2、Lp-PLA2及IGF-1水平与病情的相关性分析[J]. 检验医学, 2022, 37(9): 826-830.
[5]	翟莎娜, 孙清海, 余永武, 叶芳, 刘茂东. 万古霉素联合美罗培南对PDRP患者疗效及血清TNF-α、PCT、IL-6水平和腹膜液WBC计数的影响[J]. 检验医学, 2022, 37(4): 360-364.
[6]	赵倩, 胡红霞. 血清ACTA、LXA4、Tau蛋白在HIE患儿预后评估中的价值[J]. 检验医学, 2022, 37(11): 1057-1061.
[7]	何亚亚, 陈闪闪, 李永胜, 刘娟. AS患者sLAIR-1和LAIR-1 mRNA的表达及其与疾病活动度的关系[J]. 检验医学, 2022, 37(10): 915-920.
[8]	范桃红, 宋志明, 安元元, 刘路阳, 董凤娟. 原发性高血压病患者运动血压与VCAM-1、sICAM-1和FMD的相关性[J]. 检验医学, 2021, 36(4): 404-407.
[9]	王科惠, 黄韵, 张正银, 王亚婷, 薛玉芹, 蔡苏芳, 樊超, 金英, 郑怡菁, 常金凤. IL-6、CRP和血清过敏原检测对急性荨麻疹的临床价值[J]. 检验医学, 2021, 36(3): 300-303.
[10]	王之丰, 周洋, 丁怡娜, 党建红, 胡电, 金志军. 外周血炎症因子、凝血指标在评估子宫内膜异位症患者盆腔粘连中的价值[J]. 检验医学, 2021, 36(10): 1050-1054.
[11]	刘春林, 徐波, 陈弟, 张莉, 王飞英, 徐红云, 刘畅, 吕红玲. 感染性糖尿病足病原菌分布及耐药性分析[J]. 检验医学, 2019, 34(6): 513-517.
[12]	邵小群, 陈捷, 王世俊, 冯旭慧. 老年2型糖尿病肾病与FGF-21、脂联素及胰岛β细胞功能的相关性分析[J]. 检验医学, 2016, 31(6): 462-466.
[13]	丁彬彬, 邬建民, 介勇, 孙荣莲, 王晓燕. 阿尔茨海默病和血管性痴呆患者血清炎症因子和生化指标的检测及临床意义[J]. 检验医学, 2016, 31(5): 363-367.
[14]	赵静静, 王伟灵, 周丽霞, 杨沁彤, 张莹, 赵延荣, 邢嘉翌. FIB基因rs6056位点单核苷酸多态性及FIB浓度与糖尿病足的相关性研究[J]. 检验医学, 2015, 30(4): 376-380.
[15]	梁晓谊, 朱海英, 刘笑梅, 潘敏. 两组中药方剂对糖尿病足产ESBLs大肠埃希菌和MRSA体外药物敏感性试验结果分析[J]. 检验医学, 2015, 30(3): 261-264.